In a landmark agreement, the U.S. and Australia are collaborating to secure and develop critical minerals and rare earths supply chains crucial for advanced technologies and defense. This joint effort focuses on investment, project selection, and streamlined permitting processes to enhance resilience and market fairness.
In a surprising turn of events, the FDA has allowed Sarepta Therapeutics to resume shipments of its gene therapy, Elevidys, for younger Duchenne muscular dystrophy patients who can walk, despite concerns over previous fatalities.
